Barclays analyst Andrew Mok raised the firm’s price target on Oscar Health (OSCR) to $13 from $11 and keeps an Underweight rating on the shares following the Q3 report. The company is putting though a weighted-average rate increase of 28%, with more competitive products in bronze and gold tiers, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: